Ono Pharmaceutical Co., Ltd. – Product Pipeline Review

Global Markets Direct’s, ‘Ono Pharmaceutical Co., Ltd. – Product Pipeline Review – 2016’, provides an overview of the Ono Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Ono Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Ono Pharmaceutical Co., Ltd.

The report provides overview of Ono Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Ono Pharmaceutical Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Ono Pharmaceutical Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Ono Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ono Pharmaceutical Co., Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ono Pharmaceutical Co., Ltd.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Ono Pharmaceutical Co., Ltd. Snapshot 7

Ono Pharmaceutical Co., Ltd. Overview 7

Key Facts 7

Ono Pharmaceutical Co., Ltd. - Research and Development Overview 8

Key Therapeutic Areas 8

Ono Pharmaceutical Co., Ltd. - Pipeline Review 13

Pipeline Products by Stage of Development 13

Pipeline Products - Monotherapy 14

Pipeline Products - Combination Treatment Modalities 15

Pipeline Products - Partnered Products 16

Partnered Products/Combination Treatment Modalities 17

Pipeline Products - Out-Licensed Products 18

Out-Licensed Products/Combination Treatment Modalities 19

Ono Pharmaceutical Co., Ltd. - Pipeline Products Glance 20

Ono Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 20

Pre-Registration Products/Combination Treatment Modalities 20

Phase III Products/Combination Treatment Modalities 21

Ono Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 22

Phase II Products/Combination Treatment Modalities 22

Phase I Products/Combination Treatment Modalities 23

Ono Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 24

Preclinical Products/Combination Treatment Modalities 24

Discovery Products/Combination Treatment Modalities 25

Ono Pharmaceutical Co., Ltd. - Drug Profiles 26

(carbidopa + levodopa prodrug) - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

abatacept - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

anamorelin hydrochloride - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

E-0001163 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

etelcalcetide hydrochloride - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

ivabradine hydrochloride - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

landiolol - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

metyrosine - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Monoclonal Antibody for Autoimmune Disease - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

nivolumab - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

ONO-2952 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

ONO-4059 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

ONO-4127 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

ONO-4232 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

ONO-4310321 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

ONO-4474 - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

ONO-7268MX1 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

ONO-7268MX2 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

ONO-8055 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

ONO-8430506 - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

ONO-8577 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

opicapone - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

oprozomib - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

salirasib - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

Small Molecule to Antagonize S1P2 - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

Small Molecule to Inhibit Protease Enzyme for Undisclosed Indication - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

Small Molecules to Antagonize Lysophosphatidic Acid Receptor 1 - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

Ono Pharmaceutical Co., Ltd. - Pipeline Analysis 99

Ono Pharmaceutical Co., Ltd. - Pipeline Products by Target 99

Ono Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 102

Ono Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 103

Ono Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 104

Ono Pharmaceutical Co., Ltd. - Dormant Projects 107

Ono Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 109

Discontinued Pipeline Product Profiles 111

arundic acid 111

asimadoline 111

ceralifimod 111

freselestat 111

gemilukast 111

ipilimumab 111

limaprost 111

methylnaltrexone bromide 112

NIP-022 112

ONO-1266 112

ONO-2506-PO 112

ONO-4053 112

ONO-4127 112

ONO-5129 112

ONO-5334 112

ONO-6126 113

ONO-8539 113

remimazolam 113

rivenprost 113

tecemotide 113

Ono Pharmaceutical Co., Ltd. - Locations And Subsidiaries 114

Head Office 114

Other Locations & Subsidiaries 115

Appendix 117

Methodology 117

Coverage 117

Secondary Research 117

Primary Research 117

Expert Panel Validation 117

Contact Us 117

Disclaimer 118

List of Tables

List of Tables

Ono Pharmaceutical Co., Ltd., Key Facts 7

Ono Pharmaceutical Co., Ltd. – Pipeline by Indication, 2016 10

Ono Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, 2016 13

Ono Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2016 14

Ono Pharmaceutical Co., Ltd. – Combination Treatment Modalities in Pipeline, 2016 15

Ono Pharmaceutical Co., Ltd. – Partnered Products in Pipeline, 2016 16

Ono Pharmaceutical Co., Ltd. – Partnered Products/ Combination Treatment Modalities, 2016 17

Ono Pharmaceutical Co., Ltd. – Out-Licensed Products in Pipeline, 2016 18

Ono Pharmaceutical Co., Ltd. – Out-Licensed Products/ Combination Treatment Modalities, 2016 19

Ono Pharmaceutical Co., Ltd. – Pre-Registration, 2016 20

Ono Pharmaceutical Co., Ltd. – Phase III, 2016 21

Ono Pharmaceutical Co., Ltd. – Phase II, 2016 22

Ono Pharmaceutical Co., Ltd. – Phase I, 2016 23

Ono Pharmaceutical Co., Ltd. – Preclinical, 2016 24

Ono Pharmaceutical Co., Ltd. – Discovery, 2016 25

Ono Pharmaceutical Co., Ltd. – Pipeline by Target, 2016 100

Ono Pharmaceutical Co., Ltd. – Pipeline by Route of Administration, 2016 102

Ono Pharmaceutical Co., Ltd. – Pipeline by Molecule Type, 2016 103

Ono Pharmaceutical Co., Ltd. – Pipeline Products by Mechanism of Action, 2016 105

Ono Pharmaceutical Co., Ltd. – Dormant Developmental Projects,2016 107

Ono Pharmaceutical Co., Ltd. – Discontinued Pipeline Products, 2016 109

Ono Pharmaceutical Co., Ltd., Other Locations 115

Ono Pharmaceutical Co., Ltd., Subsidiaries 116

List of Figures

List of Figures

Ono Pharmaceutical Co., Ltd. – Pipeline by Top 10 Indication, 2016 9

Ono Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, 2016 13

Ono Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2016 14

Ono Pharmaceutical Co., Ltd. – Partnered Products in Pipeline, 2016 16

Ono Pharmaceutical Co., Ltd. – Pipeline by Top 10 Target, 2016 99

Ono Pharmaceutical Co., Ltd. – Pipeline by Route of Administration, 2016 102

Ono Pharmaceutical Co., Ltd. – Pipeline by Molecule Type, 2016 103

Ono Pharmaceutical Co., Ltd. – Pipeline Products by Top 10 Mechanism of Action, 2016 104

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports